Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $56,576.60 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total transaction of $56,576.60. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,693,565.40. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Up 2.5%

NYSE EW opened at $94.31 on Friday. The company’s fifty day simple moving average is $85.35 and its 200-day simple moving average is $83.49. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $94.47. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market cap of $54.31 billion, a P/E ratio of 50.17, a PEG ratio of 2.31 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same period last year, the business earned $0.64 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EW. Robert W. Baird lifted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Evercore reissued an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a report on Friday, April 24th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Finally, Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $96.39.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $266,000. NewEdge Advisors LLC grew its position in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after acquiring an additional 2,665 shares in the last quarter. Sei Investments Co. grew its position in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after acquiring an additional 58,988 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its holdings in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.